We analyzed outcomes and survival predictors in three West German Study Group (WSG) randomized de-escalation trials (ADAPT-HR−/HER2+, ADAPT-TP, TP-II) in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) investigating short (12-week) neoadjuvant treatments with or without chemotherapy.
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
Annals of Oncology | | M. Graeser, O. Gluz, C. Zu Eulenburg, S. Kuemmel, R. von Schumann, M. Christgen, R. Wuerstlein, E. Pelz, H.H. Kreipe, P. Schmid, M. Thill, M. Braun, J. Potenberg, C. Schumacher, J. Tio, J. Schumacher, L. Wujak, A.D. Hartkopf, M. Just, C. Schem, K. Luedtke-Heckenkamp, F. Hilpert, A. Kentsch, R.E. Kates, U. Nitz, N. Harbeck, West German Study Group investigators
Topics: breast-cancer, chemotherapy, clinical-trials, research